HBW Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

YSL Beaute Q3 sales

This article was originally published in The Rose Sheet

Executive Summary

Yves Saint Laurent Nu women's fragrance has "performed exceptionally well" since debuting in October, but increased advertising to support the launch and to enhance the YSL image led to lower profitability in the quarter, parent Gucci announces Dec. 18. Communication and selling expenses were 22% and 20% of sales, respectively, compared to 15% and 13% the prior year period. YSL Beaute operating profit before goodwill and amortization was $20.5 mil. in the quarter, down 48.5%, Gucci says. Third quarter YSL Beaute revenues were $138.8 mil., down 14.3%, due to lower U.S. and travel retail sales. Nu was first YSL fragrance to debut under control of creative director Tom Ford (1"The Rose Sheet" July 16, p. 4). Consolidated Gucci Group sales fell 7.9% to $566.2 mil. in Q3, while net income plummeted 50.7% to $56.3 mil...

Latest Headlines
See All
UsernamePublicRestriction

Register

RS009915

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel